table of content
1 Introduction to Research & Analysis Reports
1.1 Multiple Sclerosis (MS) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Multiple Sclerosis (MS) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Multiple Sclerosis (MS) Drugs Overall Market Size
2.1 Global Multiple Sclerosis (MS) Drugs Market Size: 2023 VS 2030
2.2 Global Multiple Sclerosis (MS) Drugs Revenue, Prospects & Forecasts: 2019-2030
2.3 Global Multiple Sclerosis (MS) Drugs Sales: 2019-2030
3 Company Landscape
3.1 Top Multiple Sclerosis (MS) Drugs Players in Global Market
3.2 Top Global Multiple Sclerosis (MS) Drugs Companies Ranked by Revenue
3.3 Global Multiple Sclerosis (MS) Drugs Revenue by Companies
3.4 Global Multiple Sclerosis (MS) Drugs Sales by Companies
3.5 Global Multiple Sclerosis (MS) Drugs Price by Manufacturer (2019-2024)
3.6 Top 3 and Top 5 Multiple Sclerosis (MS) Drugs Companies in Global Market, by Revenue in 2023
3.7 Global Manufacturers Multiple Sclerosis (MS) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Players in Global Market
3.8.1 List of Global Tier 1 Multiple Sclerosis (MS) Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Multiple Sclerosis (MS) Drugs Market Size Markets, 2023 & 2030
4.1.2 Copaxone (Glatiramer Acetate, Copolymer 1)
4.1.3 Novantrone (Mitoxantrone)
4.1.4 Gilenya (Fingolimod, Fty720)
4.1.5 Aubagio (Teriflunomide)
4.1.6 Tecfidera (Dimethyl Fumarate)
4.1.7 Firategrast (Sb683699, T-0047)
4.1.8 Siponimod (Baf312)
4.1.9 Others
4.2 By Type - Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
4.2.1 By Type - Global Multiple Sclerosis (MS) Drugs Revenue, 2019-2024
4.2.2 By Type - Global Multiple Sclerosis (MS) Drugs Revenue, 2025-2030
4.2.3 By Type - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
4.3 By Type - Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
4.3.1 By Type - Global Multiple Sclerosis (MS) Drugs Sales, 2019-2024
4.3.2 By Type - Global Multiple Sclerosis (MS) Drugs Sales, 2025-2030
4.3.3 By Type - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
4.4 By Type - Global Multiple Sclerosis (MS) Drugs Price (Manufacturers Selling Prices), 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Multiple Sclerosis (MS) Drugs Market Size, 2023 & 2030
5.1.2 RRMS
5.1.3 SPMS
5.1.4 PPMS
5.1.5 PRMS
5.2 By Application - Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
5.2.1 By Application - Global Multiple Sclerosis (MS) Drugs Revenue, 2019-2024
5.2.2 By Application - Global Multiple Sclerosis (MS) Drugs Revenue, 2025-2030
5.2.3 By Application - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
5.3 By Application - Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
5.3.1 By Application - Global Multiple Sclerosis (MS) Drugs Sales, 2019-2024
5.3.2 By Application - Global Multiple Sclerosis (MS) Drugs Sales, 2025-2030
5.3.3 By Application - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
5.4 By Application - Global Multiple Sclerosis (MS) Drugs Price (Manufacturers Selling Prices), 2019-2030
6 Sights by Region
6.1 By Region - Global Multiple Sclerosis (MS) Drugs Market Size, 2023 & 2030
6.2 By Region - Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
6.2.1 By Region - Global Multiple Sclerosis (MS) Drugs Revenue, 2019-2024
6.2.2 By Region - Global Multiple Sclerosis (MS) Drugs Revenue, 2025-2030
6.2.3 By Region - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
6.3 By Region - Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
6.3.1 By Region - Global Multiple Sclerosis (MS) Drugs Sales, 2019-2024
6.3.2 By Region - Global Multiple Sclerosis (MS) Drugs Sales, 2025-2030
6.3.3 By Region - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
6.4 North America
6.4.1 By Country - North America Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.4.2 By Country - North America Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.4.3 US Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.4.4 Canada Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.4.5 Mexico Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5 Europe
6.5.1 By Country - Europe Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.5.2 By Country - Europe Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.5.3 Germany Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.4 France Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.5 U.K. Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.6 Italy Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.7 Russia Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.8 Nordic Countries Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.9 Benelux Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6 Asia
6.6.1 By Region - Asia Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.6.2 By Region - Asia Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.6.3 China Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6.4 Japan Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6.5 South Korea Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6.6 Southeast Asia Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6.7 India Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.7 South America
6.7.1 By Country - South America Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.7.2 By Country - South America Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.7.3 Brazil Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.7.4 Argentina Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.8.2 By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.8.3 Turkey Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.8.4 Israel Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.8.5 Saudi Arabia Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.8.6 UAE Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
7 Manufacturers & Brands Profiles
7.1 Bayer AG
7.1.1 Bayer AG Company Summary
7.1.2 Bayer AG Business Overview
7.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Major Product Offerings
7.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.1.5 Bayer AG Key News & Latest Developments
7.2 Bayhill Therapeutics
7.2.1 Bayhill Therapeutics Company Summary
7.2.2 Bayhill Therapeutics Business Overview
7.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.2.5 Bayhill Therapeutics Key News & Latest Developments
7.3 Biogen Idec
7.3.1 Biogen Idec Company Summary
7.3.2 Biogen Idec Business Overview
7.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Major Product Offerings
7.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.3.5 Biogen Idec Key News & Latest Developments
7.4 Cinnagen
7.4.1 Cinnagen Company Summary
7.4.2 Cinnagen Business Overview
7.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Major Product Offerings
7.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.4.5 Cinnagen Key News & Latest Developments
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Company Summary
7.5.2 Daiichi Sankyo Business Overview
7.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Major Product Offerings
7.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.5.5 Daiichi Sankyo Key News & Latest Developments
7.6 Eli Lilly
7.6.1 Eli Lilly Company Summary
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Major Product Offerings
7.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.6.5 Eli Lilly Key News & Latest Developments
7.7 Fast Forward Llc
7.7.1 Fast Forward Llc Company Summary
7.7.2 Fast Forward Llc Business Overview
7.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Major Product Offerings
7.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.7.5 Fast Forward Llc Key News & Latest Developments
7.8 Antisense Therapeutics
7.8.1 Antisense Therapeutics Company Summary
7.8.2 Antisense Therapeutics Business Overview
7.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.8.5 Antisense Therapeutics Key News & Latest Developments
7.9 Apitope
7.9.1 Apitope Company Summary
7.9.2 Apitope Business Overview
7.9.3 Apitope Multiple Sclerosis (MS) Drugs Major Product Offerings
7.9.4 Apitope Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.9.5 Apitope Key News & Latest Developments
7.10 Five Prime Therapeutics
7.10.1 Five Prime Therapeutics Company Summary
7.10.2 Five Prime Therapeutics Business Overview
7.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.10.5 Five Prime Therapeutics Key News & Latest Developments
7.11 Genmab
7.11.1 Genmab Company Summary
7.11.2 Genmab Business Overview
7.11.3 Genmab Multiple Sclerosis (MS) Drugs Major Product Offerings
7.11.4 Genmab Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.11.5 Genmab Key News & Latest Developments
7.12 Artielle Immunotherapeutics
7.12.1 Artielle Immunotherapeutics Company Summary
7.12.2 Artielle Immunotherapeutics Business Overview
7.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.12.5 Artielle Immunotherapeutics Key News & Latest Developments
7.13 Genzyme
7.13.1 Genzyme Company Summary
7.13.2 Genzyme Business Overview
7.13.3 Genzyme Multiple Sclerosis (MS) Drugs Major Product Offerings
7.13.4 Genzyme Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.13.5 Genzyme Key News & Latest Developments
7.14 Glaxosmithkline
7.14.1 Glaxosmithkline Company Summary
7.14.2 Glaxosmithkline Business Overview
7.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Major Product Offerings
7.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.14.5 Glaxosmithkline Key News & Latest Developments
7.15 Gw Pharmaceuticals
7.15.1 Gw Pharmaceuticals Company Summary
7.15.2 Gw Pharmaceuticals Business Overview
7.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Major Product Offerings
7.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.15.5 Gw Pharmaceuticals Key News & Latest Developments
7.16 Innate Immunotherapeutics
7.16.1 Innate Immunotherapeutics Company Summary
7.16.2 Innate Immunotherapeutics Business Overview
7.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.16.5 Innate Immunotherapeutics Key News & Latest Developments
8 Global Multiple Sclerosis (MS) Drugs Production Capacity, Analysis
8.1 Global Multiple Sclerosis (MS) Drugs Production Capacity, 2019-2030
8.2 Multiple Sclerosis (MS) Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Multiple Sclerosis (MS) Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Multiple Sclerosis (MS) Drugs Supply Chain Analysis
10.1 Multiple Sclerosis (MS) Drugs Industry Value Chain
10.2 Multiple Sclerosis (MS) Drugs Upstream Market
10.3 Multiple Sclerosis (MS) Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Multiple Sclerosis (MS) Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
